Adult patients with ADHD commonly report an improvement in behavioural symptoms when using
cannabis with some reporting a preference towards cannabis over their ADHD stimulant
medication. The EMA-C study aims to investigate the effects of a cannabis based medication,
Sativex Oromucosal Spray on behaviour and cognition in adults with ADHD.
This will be carried out by conducting a placebo controlled trial. 30 adults with ADHD will
take Sativex or a dummy medication (a placebo) every day for 6 weeks. There is a 50% chance
of receiving the Sativex or Placebo. Measures of behaviour and cognition will be taken before
and after 6 weeks of treatment. We hypothesise that treatment with Sativex will result in
improvements in behaviour and cognition above that of the placebo group.